Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125615341 | 12561534 | 1 | I | 201006 | 20140116 | 20160715 | 20160715 | EXP | JP-CIPLA LTD.-2014JP00043 | CIPLA | UEDA N, NAKAYAMA M, MATSUZAKI K, YAMAMOTO Y, TAKEDA K, NAKATA W, ARAI Y ET.AL.,. A CASE OF PORTAL VEIN THROMBOSIS DURING CHEMOTHERAPY FOR BLADDER CANCER.. UROLOGY BULLETIN. 2013;59 (7):449 TO 452 | 53.00 | YR | M | Y | 82.00000 | KG | 20160715 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125615341 | 12561534 | 1 | PS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | UNK | U | U | 0 | ||||||||
| 125615341 | 12561534 | 2 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | U | U | 0 | ||||||||||
| 125615341 | 12561534 | 3 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | U | U | 0 | ||||||||||
| 125615341 | 12561534 | 4 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | UNK, MVAC THERAPY | U | U | 0 | ||||||||
| 125615341 | 12561534 | 5 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | UNK, GC THERAPY | U | U | 0 | ||||||||
| 125615341 | 12561534 | 6 | SS | CISPLATIN. | CISPLATIN | 1 | U | U | 0 | ||||||||||
| 125615341 | 12561534 | 7 | SS | METHOTREXATE. | METHOTREXATE | 1 | Unknown | UNK | Y | U | 0 | ||||||||
| 125615341 | 12561534 | 8 | SS | METHOTREXATE. | METHOTREXATE | 1 | Y | U | 0 | ||||||||||
| 125615341 | 12561534 | 9 | SS | METHOTREXATE. | METHOTREXATE | 1 | Y | U | 0 | ||||||||||
| 125615341 | 12561534 | 10 | SS | Doxorubicin | DOXORUBICIN | 1 | Unknown | UNK | Y | U | 0 | ||||||||
| 125615341 | 12561534 | 11 | SS | Doxorubicin | DOXORUBICIN | 1 | Y | U | 0 | ||||||||||
| 125615341 | 12561534 | 12 | SS | Doxorubicin | DOXORUBICIN | 1 | Y | U | 0 | ||||||||||
| 125615341 | 12561534 | 13 | SS | Vinblastine | VINBLASTINE | 1 | Unknown | UNK | Y | U | 0 | ||||||||
| 125615341 | 12561534 | 14 | SS | Vinblastine | VINBLASTINE | 1 | Y | U | 0 | ||||||||||
| 125615341 | 12561534 | 15 | SS | Vinblastine | VINBLASTINE | 1 | Y | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125615341 | 12561534 | 1 | Metastases to lymph nodes |
| 125615341 | 12561534 | 2 | Transitional cell carcinoma |
| 125615341 | 12561534 | 3 | Bladder cancer |
| 125615341 | 12561534 | 4 | Bladder cancer |
| 125615341 | 12561534 | 5 | Transitional cell carcinoma |
| 125615341 | 12561534 | 6 | Metastases to lymph nodes |
| 125615341 | 12561534 | 7 | Transitional cell carcinoma |
| 125615341 | 12561534 | 8 | Metastases to lymph nodes |
| 125615341 | 12561534 | 9 | Bladder cancer |
| 125615341 | 12561534 | 10 | Metastases to lymph nodes |
| 125615341 | 12561534 | 11 | Transitional cell carcinoma |
| 125615341 | 12561534 | 12 | Bladder cancer |
| 125615341 | 12561534 | 13 | Metastases to lymph nodes |
| 125615341 | 12561534 | 14 | Transitional cell carcinoma |
| 125615341 | 12561534 | 15 | Bladder cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125615341 | 12561534 | OT |
| 125615341 | 12561534 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125615341 | 12561534 | Disease progression | |
| 125615341 | 12561534 | Portal vein thrombosis | |
| 125615341 | 12561534 | Sepsis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |